Sunday, May 05, 2024
Most with type 2 diabetes achieve remission with AI-enabled precision treatment technology. An intervention program powered by artificial intelligence and data collected by sensors was linked to a type 2 diabetes remission rate of more than 80%.
The AI-Enabled Precision Treatment Technology is a dynamic representation of the metabolism of a person with type 2 diabetes. The program employs a machine learning predictive model using data from food logs and multiple sensors, including continuous glucose monitoring, fitness watches and comprehensive blood tests. The technology provides individualized and timely recommendations through a mobile app to users and their care teams. The service also includes access to healthcare providers and coaches.
The findings were presented at the American Diabetes Association Scientific Sessions. The outcome of the results demonstrates the potential of The AI-Enabled Precision Treatment Technology to change the conventional, medication-driven management of type 2 diabetes to achieving remission of type 2 diabetes with a life with reduced or free of medication in a large proportion of people. Precision lifestyle changes implemented by continued inputs delivered digitally by artificial intelligence have the potential to deliver both glycemic and extra glycemic benefits.
During RCT, adults with type 2 diabetes randomly assigned to use the AI-Enabled Precision Treatment Platform (n = 199) or receive standard of care (n = 63) for 180 days. Change in HbA1c from baseline to 180 days and the percentage of participants achieving type 2 diabetes remission were the primary outcomes. All nine participants in the intervention group who used insulin at baseline stopped using insulin prior to 90 days. In interim analysis, 94.9% of participants in the intervention group reached an HbA1c of less than 6.5% at 180 days using no medications or metformin only, and 83.9% achieved diabetes remission based on ADA criteria.
The recent consensus statement of ADA recommends a simplified criterion for diabetes remission (HbA1c <6.5% [48 mmol/mol] and at least 3 months off glucose-lowering medications), which helps standardize future studies. The consensus definition excludes those achieving remission through medications.
It was good to see the magnitude of remission of diabetes achieved in the study, validating the power of understanding the distinctions of each individual’s unique metabolism to provide personalised recommendations; another impressive finding is that remission was independent of the level of weight loss.
The intervention group had reductions in most clinical and biochemical parameters. Mean HbA1c dropped from 9% at baseline to 5.7% at 180 days (P < .001). The 3.3% reduction in the intervention was greater than the 0.4% HbA1c reduction observed in the standard of care group (P < .0001).
This platform offers thousands of parameters in a single dashboard to assist health coaches and doctors in deciding quickly. Clinical trials showed that the Platform assist not only to reverse type 2 diabetes but also improves the condition of dyslipidemia, hypertension, obesity, fatty liver, pancreas B cell dysfunction, inflammation and mental health of the patient. Because the AI-Enabled Precision Treatment program addresses the root cause of a disrupted metabolism, this approach can be applied to multiple cardiometabolic diseases.
Dr Shahjada Selim, MBBS, MD (Endocrinology), MACE (USA). Currently serving as an Associate Professor in Endocrinology at Bangabandhu Sheikh Mujib Medical University Hospital, Dr Selim specialises in Diabetes, Thyroid Disorders, Obesity, Metabolic Disorders, and Sexual Dysfunctions.
